BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37468049)

  • 1. Gut Microbiota and Uremic Retention Solutes in Adults With Moderate CKD: A 6-Day Controlled Feeding Study.
    Wiese GN; Biruete A; Stremke ER; Lindemann SR; Jannasch A; Moorthi RN; Moe SM; Swanson KS; Cross TW; Hill Gallant KM
    J Ren Nutr; 2024 Jan; 34(1):26-34. PubMed ID: 37468049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered gut microbiota and gut-derived p-cresyl sulfate serum levels in peritoneal dialysis patients.
    Bao M; Zhang P; Guo S; Zou J; Ji J; Ding X; Yu X
    Front Cell Infect Microbiol; 2022; 12():639624. PubMed ID: 36237423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
    Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G
    Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary Phosphorus Levels Influence Protein-Derived Uremic Toxin Production in Nephrectomized Male Rats.
    Cladis DP; Burstad KM; Biruete A; Jannasch AH; Cooper BR; Hill Gallant KM
    Nutrients; 2024 Jun; 16(12):. PubMed ID: 38931160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diet Quality and Protein-Bound Uraemic Toxins: Investigation of Novel Risk Factors and the Role of Microbiome in Chronic Kidney Disease.
    McFarlane C; Krishnasamy R; Stanton T; Savill E; Snelson M; Mihala G; Morrison M; Johnson DW; Campbell KL
    J Ren Nutr; 2022 Sep; 32(5):542-551. PubMed ID: 34776340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The fecal microbiome and serum concentrations of indoxyl sulfate and p-cresol sulfate in cats with chronic kidney disease.
    Summers SC; Quimby JM; Isaiah A; Suchodolski JS; Lunghofer PJ; Gustafson DL
    J Vet Intern Med; 2019 Mar; 33(2):662-669. PubMed ID: 30561098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
    Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
    Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.
    Rossi M; Johnson DW; Morrison M; Pascoe EM; Coombes JS; Forbes JM; Szeto CC; McWhinney BC; Ungerer JP; Campbell KL
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):223-31. PubMed ID: 26772193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Resveratrol Supplementation Reduce Uremic Toxin Plasma Levels From the Gut Microbiota in Nondialyzed Patients With Chronic Kidney Disease?
    Alvarenga L; Cardozo LFMF; Leal VO; Kemp JA; Saldanha JF; Ribeiro-Alves M; Meireles T; Nakao LS; Mafra D
    J Ren Nutr; 2022 Nov; 32(6):685-691. PubMed ID: 35122992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Synbiotic Treatment on the Levels of Gut-Derived Uremic Toxins, Inflammation, and Gut Microbiome of Chronic Kidney Disease Patients-A Randomized Trial.
    Mitrović M; Stanković-Popović V; Tolinački M; Golić N; Soković Bajić S; Veljović K; Nastasijević B; Soldatović I; Svorcan P; Dimković N
    J Ren Nutr; 2023 Mar; 33(2):278-288. PubMed ID: 35995418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Accumulation of Gut Microbiome-derived Indoxyl Sulfate and P-Cresyl Sulfate in Patients With End-stage Renal Disease.
    Lin X; Liang W; Li L; Xiong Q; He S; Zhao J; Guo X; Xiang S; Zhang P; Wang H; Ying C; Yao Y; Zuo X
    J Ren Nutr; 2022 Sep; 32(5):578-586. PubMed ID: 34736844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of ß-Glucan Prebiotic on Kidney Function, Uremic Toxins and Gut Microbiome in Stage 3 to 5 Chronic Kidney Disease (CKD) Predialysis Participants: A Randomized Controlled Trial.
    Ebrahim Z; Proost S; Tito RY; Raes J; Glorieux G; Moosa MR; Blaauw R
    Nutrients; 2022 Feb; 14(4):. PubMed ID: 35215453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
    Cooper TE; Khalid R; Chan S; Craig JC; Hawley CM; Howell M; Johnson DW; Jaure A; Teixeira-Pinto A; Wong G
    Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013631. PubMed ID: 37870148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change.
    Liu Y; Li J; Yu J; Wang Y; Lu J; Shang EX; Zhu Z; Guo J; Duan J
    J Pharm Biomed Anal; 2018 Feb; 149():425-435. PubMed ID: 29169110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in Serum Concentrations of Uremic Toxins Driven by Bifidobacterium Longum Subsp. Longum BL21 is Associated with Gut Microbiota Changes in a Rat Model of Chronic Kidney Disease.
    Dong Y; Gai Z; Han M; Xu J; Zou K
    Probiotics Antimicrob Proteins; 2024 Jun; ():. PubMed ID: 38829564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease: Contribution of Decreased Glomerular Filtration Rate.
    Pelletier CC; Croyal M; Ene L; Aguesse A; Billon-Crossouard S; Krempf M; Lemoine S; Guebre-Egziabher F; Juillard L; Soulage CO
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31683880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.
    Tang WH; Wang Z; Kennedy DJ; Wu Y; Buffa JA; Agatisa-Boyle B; Li XS; Levison BS; Hazen SL
    Circ Res; 2015 Jan; 116(3):448-55. PubMed ID: 25599331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial.
    Ramos CI; Armani RG; Canziani MEF; Dalboni MA; Dolenga CJR; Nakao LS; Campbell KL; Cuppari L
    Nephrol Dial Transplant; 2019 Nov; 34(11):1876-1884. PubMed ID: 29939302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.
    Fernandez-Prado R; Esteras R; Perez-Gomez MV; Gracia-Iguacel C; Gonzalez-Parra E; Sanz AB; Ortiz A; Sanchez-Niño MD
    Nutrients; 2017 May; 9(5):. PubMed ID: 28498348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.